BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 17456528)

  • 61. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment.
    Mínguez S; Latorre I; Mateo L; Lacoma A; Diaz J; Olivé A; Domínguez J
    Clin Rheumatol; 2012 May; 31(5):785-94. PubMed ID: 22271230
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of interferon-gamma release assay (T-SPOT.TB(™) ) for diagnosis of tuberculosis infection in rheumatic disease patients.
    Jiang B; Ding H; Zhou L; Chen X; Chen S; Bao C
    Int J Rheum Dis; 2016 Jan; 19(1):38-42. PubMed ID: 26820838
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [New immunological tests in the diagnosis of tuberculosis].
    Lagrange PH; Simonney N; Herrmann JL
    Rev Mal Respir; 2007 Apr; 24(4 Pt 1):453-72. PubMed ID: 17468703
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
    Balbir-Gurman A; Lidgi M; Elkayam O
    Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Measurement of phenotype and absolute number of circulating heparin-binding hemagglutinin, ESAT-6 and CFP-10, and purified protein derivative antigen-specific CD4 T cells can discriminate active from latent tuberculosis infection.
    Hutchinson P; Barkham TM; Tang W; Kemeny DM; Chee CB; Wang YT
    Clin Vaccine Immunol; 2015 Feb; 22(2):200-12. PubMed ID: 25520147
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of Quantiferon-TB-Gold in Tube(®) test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice.
    García-Gasalla M; Fernández-Baca V; Juan-Mas A; Payeras-Cifre A; Cifuentes-Luna C; Taberner-Ferrer R; Riera-Oliver J; Ros-Villamajó I; Navarro-Fernández V; Morey Torrandell C; Gallegos-Alvarez C; Mir-Villadrich I
    Enferm Infecc Microbiol Clin; 2013 Feb; 31(2):76-81. PubMed ID: 22902246
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection.
    Mazurek GH; LoBue PA; Daley CL; Bernardo J; Lardizabal AA; Bishai WR; Iademarco MF; Rothel JS
    JAMA; 2001 Oct; 286(14):1740-7. PubMed ID: 11594899
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Mycobacterium tuberculosis Dormancy Antigen Differentiates Latently Infected Bacillus Calmette-Guérin-vaccinated Individuals.
    Peña D; Rovetta AI; Hernández Del Pino RE; Amiano NO; Pasquinelli V; Pellegrini JM; Tateosian NL; Rolandelli A; Gutierrez M; Musella RM; Palmero DJ; Gherardi MM; Iovanna J; Chuluyan HE; García VE
    EBioMedicine; 2015 Aug; 2(8):884-90. PubMed ID: 26425695
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis.
    Hougardy JM; Schepers K; Place S; Drowart A; Lechevin V; Verscheure V; Debrie AS; Doherty TM; Van Vooren JP; Locht C; Mascart F
    PLoS One; 2007 Oct; 2(10):e926. PubMed ID: 17912342
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mycobacterium tuberculosis epitope-specific interferon-g production in healthy Brazilians reactive and non-reactive to tuberculin skin test.
    Silva BC; Grassi MF; Coutinho R; Mascarenhas RE; Olavarria VN; Coutinho-Borgo A; Kalil J; Cunha Neto E; Fonseca SG
    Mem Inst Oswaldo Cruz; 2014 Dec; 109(8):999-1004. PubMed ID: 25494469
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mycobacterial interferon-γ release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome.
    Scrivo R; Sauzullo I; Mengoni F; Priori R; Coppola M; Iaiani G; DI Franco M; Vullo V; Mastroianni CM; Valesini G
    J Rheumatol; 2013 Feb; 40(2):157-65. PubMed ID: 23204217
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Profile of interferon-gamma response to latency-associated and novel in vivo expressed antigens in a cohort of subjects recently exposed to Mycobacterium tuberculosis.
    Araujo LS; da Silva NBM; da Silva RJ; Leung JAM; Mello FCQ; Saad MHF
    Tuberculosis (Edinb); 2015 Dec; 95(6):751-757. PubMed ID: 26421415
    [TBL] [Abstract][Full Text] [Related]  

  • 78. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
    Bonfiglioli KR; Ribeiro AC; Moraes JC; Saad CG; Souza FH; Calich AL; Bonfa E; Laurindo IM
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):905-11. PubMed ID: 25199003
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
    Sánchez-Moya AI; Dauden E
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.
    Garziera G; Morsch ALB; Otesbelgue F; Staub FL; Palominos PE; Brenol CV; Silva DR
    Clin Rheumatol; 2017 Aug; 36(8):1891-1896. PubMed ID: 28589321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.